Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis

HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcanes, George, Vacirca, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc. 2019
Materias:
Features
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328855/
https://www.ncbi.nlm.nih.gov/pubmed/31464835
http://dx.doi.org/10.1097/NAN.0000000000000341
_version_ 1783552805289590784
author Calcanes, George
Vacirca, Jeffrey L.
author_facet Calcanes, George
Vacirca, Jeffrey L.
author_sort Calcanes, George
collection PubMed
description HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.
format Online
Article
Text
id pubmed-7328855
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73288552020-07-13 Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis Calcanes, George Vacirca, Jeffrey L. J Infus Nurs Features HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified. Wolters Kluwer Health, Inc. 2019-09 2019-09-13 /pmc/articles/PMC7328855/ /pubmed/31464835 http://dx.doi.org/10.1097/NAN.0000000000000341 Text en © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Infusion Nurses Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Features
Calcanes, George
Vacirca, Jeffrey L.
Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title_full Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title_fullStr Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title_full_unstemmed Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title_short Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
title_sort safety profile of htx-019 administered as an intravenous infusion in patients with cancer: a retrospective analysis
topic Features
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328855/
https://www.ncbi.nlm.nih.gov/pubmed/31464835
http://dx.doi.org/10.1097/NAN.0000000000000341
work_keys_str_mv AT calcanesgeorge safetyprofileofhtx019administeredasanintravenousinfusioninpatientswithcanceraretrospectiveanalysis
AT vacircajeffreyl safetyprofileofhtx019administeredasanintravenousinfusioninpatientswithcanceraretrospectiveanalysis

Ejemplares similares